Race Oncology: Advancing Cancer Care Through G4-DNA Targeting

Race Oncology Limited (ASX: RAC) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Its lead drug, RCDS1 (E, E-bisantrene), was recently discovered to act primarily by binding to G-quadruplex (G4) DNA and RNA structures, rather than functioning as a traditional chemotherapeutic. This breakthrough mechanism targets cancer-driving genes such as MYC, inhibits key enzymes like telomerase and topoisomerase II, and increases m6A RNA modifications, which together suppress tumor growth and therapy resistance.

Race is advancing a proprietary formulation of RCDS1 (RC220) to treat multiple cancers, with potential benefits in both solid tumors and blood cancers such as acute myeloid leukemia. The company’s strategy includes exploring drug combinations, developing biomarker tests, and building global partnerships. With collaborations spanning major institutions and a strong clinical pipeline, Race Oncology aims to address unmet patient needs and expand access to innovative oncology treatments worldwide.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com